Bisphosphonate treatment of bone metastases and hypercalcemia of malignancy.

Bone metastases and hypercalcemia are common in patients with advanced cancer and may present major problems for physicians treating these patients. The recent development of the bisphosphonates has improved therapy for these two conditions. These compounds, pyrophosphate analogs with a P-C-P backbone, which binds tightly to calcified bone matrix, include etidronate, clodronate, and pamidronate. All three are useful for the treatment of hypercalcemia, but pamidronate seems to be the most effective. Currently investigational in the United States, pamidronate is now in active clinical testing. The author discusses the administration, dosage and side effects, and results of current studies.
AuthorsR E Coleman
JournalOncology (Williston Park, N.Y.) (Oncology (Williston Park)) Vol. 5 Issue 8 Pg. 55-60; discussion 60-2, 65 (Aug 1991) ISSN: 0890-9091 [Print] UNITED STATES
PMID1834153 (Publication Type: Journal Article)
Chemical References
  • Diphosphonates
  • Clodronic Acid
  • Etidronic Acid
  • pamidronate
  • Animals
  • Bone Neoplasms (drug therapy, pathology, secondary)
  • Bone and Bones (drug effects, pathology)
  • Clodronic Acid (therapeutic use)
  • Diphosphonates (therapeutic use)
  • Etidronic Acid (therapeutic use)
  • Humans
  • Hypercalcemia (drug therapy, etiology)
  • Neoplasms (complications)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: